Preliminary evidence of effects of potassium chloride on a metabolomic path to diabetes and cardiovascular disease.
Metabolomics
; 16(7): 75, 2020 06 18.
Article
in En
| MEDLINE
| ID: mdl-32556595
ABSTRACT
INTRODUCTION:
Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors.OBJECTIVE:
We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile.METHODS:
In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data.RESULTS:
Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11).CONCLUSIONS:
KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile. CLINICAL TRIALS REGISTRY Clinicaltrials.gov identifier NCT02236598; https//clinicaltrials.gov/ct2/show/NCT02236598.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Potassium Chloride
/
Cardiovascular Diseases
/
Diabetes Mellitus
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Metabolomics
Year:
2020
Document type:
Article
Affiliation country:
United States